Literature DB >> 14962911

NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.

Ting-Lei Gu1, Zuzana Tothova, Blanca Scheijen, James D Griffin, D Gary Gilliland, David W Sternberg.   

Abstract

Between 30% and 50% of patients with advanced-stage anaplastic large-cell lymphoma (ALCL) harbor the balanced chromosomal rearrangement t(2;5)(p23;q35), which results in the generation of the fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). To further study survival signaling by NPMALK, we generated Ba/F3 cell lines with either inducible or constitutive expression of NPM-ALK and examined the regulation of the AKT target FOXO3a. We hypothesized that NPM-ALK signaling through phosphoinositol 3-kinase (PI 3-kinase) and AKT would regulate FOXO3a, a member of the forkhead family of transcription factors, thereby stimulating proliferation and blocking programmed cell death in NPM-ALK-transformed cells. In Ba/F3 cells with induced or constitutive expression of NPM-ALK, concomitant AKT activation and phosphorylation of its substrate, FOXO3a, was observed. In addition, transient expression of NPM-ALK in U-20S cells inhibited FOXO3a-mediated transactivation of reporter gene expression. Furthermore, NPM-ALK-induced FOXO3a phosphorylation in Ba/F3 cells resulted in nuclear exclusion of this transcriptional regulator, up-regulation of cyclin D2 expression, and down-regulation of p27(kip1) and Bim-1 expression. NPMALK reversal of proliferation arrest and of p27(kip1) induction was dependent on the phosphorylation of FOXO3a. Thus, FOXO3a is a barrier to hematopoietic transformation that is overcome by phosphorylation and cytoplasmic relocalization induced by the expression of NPM-ALK.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14962911     DOI: 10.1182/blood-2003-03-0820

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.

Authors:  Rajan Dewar; Sing-Tsung Chen; Heather Yeckes-Rodin; Kenneth Miller; Roya Khosravi-Far
Journal:  Cancer Biol Ther       Date:  2011-03-15       Impact factor: 4.742

Review 2.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

3.  ALK positively regulates MYCN activity through repression of HBP1 expression.

Authors:  Shana Claeys; Geertrui Denecker; Kaat Durinck; Bieke Decaesteker; Liselot M Mus; Siebe Loontiens; Suzanne Vanhauwaert; Kristina Althoff; Caroline Wigerup; Daniel Bexell; Emmy Dolman; Kai-Oliver Henrich; Lea Wehrmann; Ellen M Westerhout; Jean-Baptiste Demoulin; Candy Kumps; Tom Van Maerken; Genevieve Laureys; Christophe Van Neste; Bram De Wilde; Olivier De Wever; Frank Westermann; Rogier Versteeg; Jan J Molenaar; Sven Påhlman; Johannes H Schulte; Katleen De Preter; Frank Speleman
Journal:  Oncogene       Date:  2018-12-11       Impact factor: 9.867

Review 4.  ALK-immunoreactive neoplasms.

Authors:  Parham Minoo; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

5.  Evidence for AKT-independent regulation of FOXO1 and FOXO3 in haematopoietic stem and progenitor cells.

Authors:  Raymond Liang; Pauline Rimmelé; Carolina L Bigarella; Safak Yalcin; Saghi Ghaffari
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 6.  The Role of Forkhead Box 1 (FOXO1) in the Immune System: Dendritic Cells, T Cells, B Cells, and Hematopoietic Stem Cells.

Authors:  Adriana Alicia Cabrera-Ortega; Daniel Feinberg; Youde Liang; Carlos Rossa; Dana T Graves
Journal:  Crit Rev Immunol       Date:  2017       Impact factor: 2.214

7.  p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.

Authors:  Chiara Ambrogio; Claudia Voena; Andrea D Manazza; Roberto Piva; Ludovica Riera; Laura Barberis; Carlotta Costa; Guido Tarone; Paola Defilippi; Emilio Hirsch; Elisabetta Boeri Erba; Shabaz Mohammed; Ole N Jensen; Giorgio Palestro; Giorgio Inghirami; Roberto Chiarle
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

Review 8.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

9.  Remarkably reduced expression of FoxO3a in metaplastic colorectum, primary colorectal cancer and liver metastasis.

Authors:  Le-Ya He; Xin Wei; Lei Du; Lu Liu; Feng Xu; Jiang Min; Chuan Li; De-Ding Tao; Quan Chen; Jun-Bo Hu; Jian-Ping Gong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.